Blar i forfatter "Karlsen, Iselin"

Viser treff 1-3 av 3

    • Docetaxel in liposomes: the effect of lipid composition on the achieved drug entrapment 

      Karlsen, Iselin (Mastergradsoppgave; Master thesis, 2018-05-15)
      INTRODUCTION: Docetaxel (DOC) is a potent anticancer drug but has several limitations such as poor solubility. The currently commercially available formulation of DOC is limited by reported serious side effects which either is attributed to the drug itself or the solvent used. Nanomedicine has been used for improving the therapeutic outcome of several drugs, but so far there are none available with ...

    • Docetaxel Liposomes - A formulation Screening Study 

      Karlsen, Iselin; Skalko-Basnet, Natasa; Holsæter, Ann Mari (Conference object; Konferansebidrag, 2019)
      <p>Docetaxel (DOC) is a potent anticancer drug with several limitations, including poor solubility and the reported serious side effects, attributed to either the drug itself or the solvent used. Thus, it is interesting to entrap the drug into liposomes in order to solubilize the drug and improve the therapeutic outcome. <p>The fist aim of this study was to establish a small-scale screening method ...

    • How docetaxel entrapment, vesicle size, zeta potential and stability change with liposome composition–A formulation screening study 

      Holsæter, Ann Mari; Wizgird, Kristina; Karlsen, Iselin; Hemmingsen, Jeanette Frimand; Brandl, Martin; Skalko-Basnet, Natasa (Journal article; Tidsskriftartikkel; Peer reviewed, 2022-07-21)
      Limitations of the anticancer drug product Taxotere® have encouraged researchers to entrap the active ingredient docetaxel (DTX) into nanocarriers such as liposomes. However, until now no DTX-liposome formulation has reached the clinic. Hence, in the present study, different Soy-PC based DTX-liposome formulations were screened in an attempt to identify lipid-compositions with promising DTX-entrapment ...